GlassScriptPhysician profile
Benhanan Ways
NPI 1073188967
$2,645.43
in general payments reported to CMS, 2019-2025
22 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,017 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,556 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.43 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $319.34 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.13 | 2024-2025 | Jardiance |
| Amgen INC. | $281.08 | 2024-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $240.35 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Kiniksa Pharmaceuticals International, Plc | $193.84 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $191.36 | 2025 | Attruby |
| Novo Nordisk INC | $163.47 | 2024-2025 | Wegovy, Ozempic |
| Harmony Biosciences LLC | $114.86 | 2025 | |
| Glaxosmithkline, LLC. | $110.70 | 2024-2025 | Nucala, Trelegy Ellipta |
| Alnylam Pharmaceuticals INC. | $107.04 | 2025 | Onpattro, Amvuttra |
| Astrazeneca Pharmaceuticals LP | $102.30 | 2024-2025 | Lokelma, Airsupra |
| Novartis Pharmaceuticals Corporation | $92.05 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $84.26 | 2024-2025 | Verquvo |
| United Therapeutics Corporation | $65.90 | 2024-2025 | Tyvaso |
| Janssen Pharmaceuticals, INC | $59.94 | 2024 | Xarelto |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $50.83 | 2025 | |
| Altathera Pharmaceuticals LLC | $50.00 | 2024-2025 | Sotalol Hydrochloride |
| Esperion Therapeutics, INC. | $41.27 | 2024 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.32 | 2025 | Lifevest |
| Takeda Pharmaceuticals U.S.A., INC. | $30.19 | 2024 | Glassia |
| Regeneron Healthcare Solutions, INC. | $16.11 | 2025 | Dupixent |
| Avadel Cns Pharmaceuticals, LLC | $13.09 | 2024 | Lumryz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benhanan Ways listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.